<ѻý>Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancerѻý> Combination may "provide meaningful antitumor activity," researchers say Sep 28, 2023
<ѻý>Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screeningѻý> News, features, and commentary about cancer-related issues Sep 28, 2023
<ѻý>The White House Cancer Moonshot Is a Dudѻý> We're failing to take simple steps to reduce one of the biggest causes of cancer Sep 22, 2023
<ѻý>TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncologyѻý> News, features, and commentary about cancer-related issues Sep 21, 2023
<ѻý>Another Win for Biomarker-Driven Thromboprophylaxis for Patients With Cancerѻý> Threefold risk reduction with enoxaparin in high-risk gastrointestinal, lung cancers Sep 21, 2023
<ѻý>Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusionѻý> News, features, and commentary about cancer-related issues Sep 15, 2023
<ѻý>Individualized SABR for Lung Tumors Yields Low Recurrence Ratesѻý> Strategy also results in low rates of severe toxic effects Sep 14, 2023
<ѻý>IMRT Best for Locally Advanced NSCLC, Study Suggestsѻý> Technique reduces risk of severe lung toxicity and radiation to the heart compared with 3D-CRT Sep 13, 2023
<ѻý>Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLCѻý> Confirmed responses reached 29.8% in heavily pretreated patients Sep 13, 2023
<ѻý>Study Questions Use of Aggressive Surgery in Early Mesotheliomaѻý> Randomized data suggest surgery increases risk of death by 28% over first 42 months Sep 12, 2023
<ѻý>Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancerѻý> Osimertinib plus chemotherapy improved PFS by nearly 9 months versus targeted agent alone Sep 12, 2023
<ѻý>First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLCѻý> Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
<ѻý>How the Chemotherapy Shortage Is Affecting Frontline Cliniciansѻý> "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
<ѻý>Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Careѻý> News, features, and commentary about cancer-related issues Sep 07, 2023
<ѻý>Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancerѻý> News, features, and commentary about cancer-related issues Sep 01, 2023
<ѻý>Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Typesѻý> More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
<ѻý>Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Careѻý> Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023
<ѻý>Multi-Cancer Early Detection: 20th-Century Fiction Becomes Realityѻý> These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
<ѻý>Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLCѻý> Approach is "potentially practice-changing," editorialist says Jul 20, 2023
<ѻý>Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Useѻý> But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
<ѻý>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortagesѻý> News, features, and commentary about cancer-related issues Jun 15, 2023
<ѻý>Hooray! A Clearer Estimate of Your Risk for Death Is Hereѻý> Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
<ѻý>TTFields Therapy Yields OS Improvement in Second-Line NSCLCѻý> However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<ѻý>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLCѻý> "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<ѻý>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Yearsѻý> Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
<ѻý>New Data in NSCLC Bolster Support for Perioperative Immunotherapyѻý> EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
<ѻý>New Standard in Operable EGFR-Positive Lung Cancerѻý> "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
<ѻý>Lung Cancer Screening Results Influence Follow-Up Adherenceѻý> Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
<ѻý>Drug Shortages Hit Oncology; Telemedicine Tops In-Person; Sniffing Out Lung Cancerѻý> News, features, and commentary about cancer-related issues May 12, 2023
<ѻý>'Potential' New Option for Operable NSCLCѻý> Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
<ѻý>FDA Allows Lower Risk Designation for Snuff Productѻý> The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
<ѻý>'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advancesѻý> News, features, and commentary about cancer-related issues Mar 03, 2023
<ѻý>Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoeѻý> News, features, and commentary about cancer-related issues Feb 24, 2023
<ѻý>AI Tool Forecasts Lung Cancer Risk From a Single CT Scanѻý> Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
<ѻý>Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recsѻý> Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
<ѻý>Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancerѻý> A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
<ѻý>Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patientsѻý> Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
<ѻý>Xeljanz Cancer Risks Detailedѻý> New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<ѻý>Lung Cancer Survival High for Patients With Early, Screen-Detected Tumorsѻý> Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
<ѻý>Lung Cancer Screening Programs Hit the Mark on Eligibility Criteriaѻý> However, adherence to follow-up screening is "suboptimal" Oct 10, 2022